Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

Company Overview

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures and markets injectable, inhaled and intranasal products. The company focuses on technically challenging medicines, including generic and proprietary products used in emergency care, respiratory treatment, diabetes management and other therapeutic areas.

Its marketed products include Primatene MIST, an over-the-counter epinephrine inhaler for temporary relief of mild, intermittent asthma symptoms; BAQSIMI, a ready-to-use nasal glucagon product for severe hypoglycemia; glucagon injection; Amphadase, a hyaluronidase product; and enoxaparin, an anticoagulant. Amphastar also maintains a development pipeline covering additional injectable, inhaled and intranasal therapies.

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar serves healthcare providers, institutions and consumers primarily in the United States, with products distributed through commercial and healthcare channels. Jack Zhang, Ph.D., is the company's chairman, president and chief executive officer.

Key Stats

• Today's Range: $25.65 to $26.79
• 50-Day Range: $19.81 to $27.39
• 52-Week Range: $16.65 to $29.52
• Volume: 437,694 shs
• Average Volume: 558,134 shs
• Market Capitalization: $1.13 billion
• P/E Ratio: 15.75
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Reduce

Amphastar Pharmaceuticals Stock Analysis - MarketRank™

Amphastar Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 666th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Amphastar Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 6 hold ratings, and 2 sell ratings.

Downside Risk

Amphastar Pharmaceuticals has a consensus price target of $22.50, representing about 15.5% downside from its current price of $26.62.

Amount of Analyst Coverage

Amphastar Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.28%

Earnings Growth

Earnings for Amphastar Pharmaceuticals are expected to grow by 5.28% in the coming year, from $2.46 to $2.59 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amphastar Pharmaceuticals is 15.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amphastar Pharmaceuticals is 15.75, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.29.

Price to Earnings Growth Ratio

Amphastar Pharmaceuticals has a PEG Ratio of 5.13. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amphastar Pharmaceuticals has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.71% of the float of Amphastar Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amphastar Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Amphastar Pharmaceuticals has recently decreased by 11.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amphastar Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amphastar Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Amphastar Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for AMPH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $763,922.00 in company stock.

Percentage Held by Insiders

29.60% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/11/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMPH
• CIK: 1297184
• Web: www.amphastar.com
• Phone: (909) 980-9484
• Fax: 909-980-8296
• Employees: 1,976
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Amphastar Pharmaceuticals: $22.50
• High Price Target: $30.00
• Low Price Target: $20.00
• Potential Upside/Downside: -15.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.69
• Trailing P/E Ratio: 15.75
• Forward P/E Ratio: 10.82
• P/E Growth: 5.13
• Net Income: $98.09 million
• Net Margins: 10.76%
• Pretax Margin: 13.98%
• Return on Equity: 14.98%
• Return on Assets: 6.96%

Debt

• Debt-to-Equity Ratio: 0.79
• Current Ratio: 2.40
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $719.89 million
• Price / Sales: 1.57
• Cash Flow: $4.25 per share
• Price / Cash Flow: 6.26
• Book Value: $17.17 per share
• Price / Book: 1.55

Miscellaneous

• Outstanding Shares: 42,540,000
• Free Float: 29,947,000
• Market Cap: $1.13 billion
• Optionable: Optionable
• Beta: 0.90